In the wake of the AstraZeneca blood clots scandal, another scion of Big Pharma, Johnson & Johnson, has been forced to halt the roll-out of their experimental COVID vaccine due to the emergence of potentially lethal “rare blood clots” in women who have took the not fully licensed corporate product.
Meanwhile, other firms are using these blood clots scandals to push the other experimental vaccine, Pfizer and Moderna’s gene-based mRNA jab – both of which have also caused a number of serious adverse reactions and injuries worldwide.
Western governments and their mainstream media partners – especially in the US and UK which are heavily invested both politically and economically in the reputation and credibility of this transnational pharmaceutical cartel, are keen to downplay any reports of adverse reactions, injuries or death due to people taking their experimental range of COVID vaccines.
None of the current range of experimental vaccines are fully licensed products and instead were allowed to bypass normal regulatory protocols and procedures because the US government issued a Emergency Use Authorization waver after claiming there was a ‘deadly pandemic raging’ and that the risk of circulating potentially dangerous and untested vaccines was outweighed by risk posed to population by dying of COVID. However, after 12 months of viewing the actual data, even by western governments’ own official statistics, it’s clear that COVID-19 posed little if any risk to the general population, and according to the governments’ own numbers, it only seriously effected the elderly with multiple long term chronic health conditions.
Fierce Pharma reports…
After drug regulators on both sides of the Atlantic revealed safety probes into Johnson & Johnson’s COVID-19 vaccine, U.S. officials are calling for an immediate pause to the rollout.
Since the vaccine’s late February emergency use authorization in the U.S., nearly 7 million people have received the shot. Six recipients of the vaccine—all women between 18 and 48—were diagnosed with rare blood clots afterward, the FDA says. One died and one is in critical condition.
The FDA on Tuesday said it’s “recommending a pause in the use of this vaccine out of an abundance of caution.”
Speaking with reporters on Tuesday, FDA acting commissioner Janet Woodcock said she expects the pause to last a “matter of days.” While the FDA and CDC investigate, officials also want to flag symptoms of the rare clots and treatment recommendations for them.
The rare blood clots need to be treated differently than typical clots, officials said. In fact, standard treatments can worsen a patient’s condition.
The cases all surfaced about one to three weeks after vaccination, FDA vaccine official Peter Marks said on the call. Warning signs include severe headache, abdominal pain, leg pain and shortness of breath. The FDA plans to revise the J&J vaccine fact sheet to include the updated information.
The pause represents a setback for the J&J vaccine as the U.S. pushes ahead with the mRNA shots from Pfizer and Moderna. AstraZeneca’s COVID-19 vaccine—which, like J&J’s, is adenovirus-based—has also raised rare blood clot concerns, and that has led to a sporadic vaccination effort in Europe, where individual countries are setting vaccine policy.
The CDC’s Advisory Committee on Immunization Practices—which reviews data and makes vaccination recommendations for the U.S.—will meet Wednesday to discuss the data. The FDA is investigating the rare clotting cases and will review the committee’s analysis.
J&J is “aware of an extremely rare disorder involving people with blood clots in combination with low platelets” in a small number of people after vaccination, the company said in a statement…
READ MORE VACCINE NEWS AT: 21st Century Wire Vaccine Files
PLEASE HELP SUPPORT OUR INDEPENDENT MEDIA PLATFORM HERE
Click this link for the original source of this article.
Author: NEWS WIRE
This content is courtesy of, and owned and copyrighted by, https://21stcenturywire.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.